Nephrol Dial Transplant (2002) 17: 1513-1517
© 2002 European Renal Association-European Dialysis and Transplant Association
Brief Report
Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus
1 Department of Internal Medicine, Keio University School of Medicine, Tokyo, 2 Kawasaki Municipal Ida Hospital and 3 Kawasaki Ekimae Clinic, Kawasaki, Japan
Background. Arterial stiffness assessed by pulse wave velocity (PWV) predicts all-cause and cardiovascular mortality in diabetic patients with end-stage renal disease. We studied the preventive effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on arterial PWV values in this population.
Methods. Twenty-two patients with normal serum lipid levels received fluvastatin (20 mg/day p.o.) or a placebo for 6 months. Their serum lipid levels, serum levels of C-reactive protein (CRP), arterial PWV, and ankle brachial indexes (ABI) were determined before, and 3 and 6 months after taking the medication to evaluate arterial stiffness.
Results. At the beginning of the follow-up, there were no differences in age, blood pressure, body mass index, serum haemoglobin A1c level, serum CRP level, serum lipid levels, PWV or ABI between the placebo- (n=10) and the fluvastatin-treated patients (n=12). After 6 months, the PWV and the serum oxidized low-density lipoprotein cholesterol (LDL-C) level increased significantly (from 1969±140 to 2326±190 cm/s and 70.4±13.8 to 91.8±15.5 U/l, respectively) in the placebo-treated patients. However, the fluvastatin group had a significantly reduced PWV (from 1991±162 to 1709±134 cm/s), oxidized LDL-C serum levels (from 89.0±9.6 to 73.0±5.8 U/l) and CRP serum levels (from 0.97±0.32 to 0.26±0.16 mg/dl) compared with those in the placebo group.
Conclusions. Long-term administration of fluvastatin prevents further worsening of arterial biomechanics in haemodialysis patients with type 2 diabetes mellitus, even in the presence of serum lipid levels in the normal range.
Keywords: ankle brachial index; end-stage renal disease; HMG-CoA reductase inhibitor; oxidized low-density lipoprotein; pulse wave velocity
Correspondence and offprint requests to: Atsuhiro Ichihara, Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Email: atzichi{at}sc.itc.keio.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. S. Orr, A. L. Dengo, J. M. Rivero, and K. P. Davy Arterial Destiffening With Atorvastatin in Overweight and Obese Middle-Aged and Older Adults Hypertension, October 1, 2009; 54(4): 763 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hiukka, J. Westerbacka, E. S. Leinonen, H. Watanabe, O. Wiklund, L. M. Hulten, J. T. Salonen, T.-P. Tuomainen, H. Yki-Jarvinen, A. C. Keech, et al. Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus J. Am. Coll. Cardiol., December 16, 2008; 52(25): 2190 - 2197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Khoshdel, S. L. Carney, B. R. Nair, and A. Gillies Better Management of Cardiovascular Diseases by Pulse Wave Velocity: Combining Clinical Practice with Clinical Research using Evidence-Based Medicine Clin. Med. Res., March 1, 2007; 5(1): 45 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Goicoechea, S. G. de Vinuesa, V. Lahera, V. Cachofeiro, F. Gomez-Campdera, A. Vega, S. Abad, and J. Luno Effects of Atorvastatin on Inflammatory and Fibrinolytic Parameters in Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S231 - S235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Covic, N. Mardare, P. Gusbeth-Tatomir, O. Prisada, R. Sascau, and D. J. A. Goldsmith Arterial wave reflections and mortality in haemodialysis patients--only relevant in elderly, cardiovascularly compromised? Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2859 - 2866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takenaka and H. Suzuki New strategy to attenuate pulse wave velocity in haemodialysis patients Nephrol. Dial. Transplant., April 1, 2005; 20(4): 811 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Larsen Pancreas Transplantation: Indications and Consequences Endocr. Rev., December 1, 2004; 25(6): 919 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Van Doornum, G McColl, and I P Wicks Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis Ann Rheum Dis, December 1, 2004; 63(12): 1571 - 1575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Afzali, A. A. Haydar, K. Vinen, and D. J.A. Goldsmith From Finland to Fatland: Beneficial Effects of Statins for Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2161 - 2168. [Abstract] [Full Text] [PDF]
|
|